Revance's RT002 meets in pair of Phase III trials for frown lines

Revance Therapeutics Inc. (NASDAQ:RVNC) said a single injection of DaxibotulinumtoxinA for Injection (RT002) met the primary and all secondary endpoints in the Phase III SAKURA 1 and SAKURA 2 trials to treat moderate to severe glabellar lines, or frown lines between the eyebrows. Revance plans

Read the full 453 word article

User Sign In